Brief: Urogen Pharma Q3 Loss Per Share $1.06
12/11/2019 13:49
Nov 12 (Reuters) - Urogen Pharma Ltd UR8.F :
* UROGEN PHARMA REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS
AND
RECENT CORPORATE DEVELOPMENTS
* Q3 LOSS PER SHARE $1.06
* UROGEN PHARMA - COMPLETED SUBMISSION OF NDA TO U.S. FDA
FOR
UGN-101 IN PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER
Source text for Eikon: ID:nBwbpdxkRa
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors